Shi-dong Xu
Harbin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
International expert consensus on immunotherapy for early-stage non-small cell lung cancer.
Journal: Translational lung cancer research
Published: June 07, 2022
Technical aspects and early results of uniportal video-assisted thoracoscopic complex segmentectomy: a 30 case-series study.
Journal: Journal of cardiothoracic surgery
Published: August 20, 2021
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer.
Journal: Translational lung cancer research
Published: June 07, 2021
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.
Journal: Nature communications
Published: April 24, 2021
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 17, 2020
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 17, 2020
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 29, 2018
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Journal: The Lancet. Oncology
Published: July 28, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026